雌激素受体-α表达与晚期非小细胞肺癌患者的生存率
Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer.
作者信息
Lund-Iversen Marius, Scott Helge, Strøm Erik H, Theiss Noah, Brustugun Odd Terje, Grønberg Bjørn H
机构信息
Department of Pathology, Oslo University Hospital, Oslo, Norway
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
出版信息
Anticancer Res. 2018 Apr;38(4):2261-2269. doi: 10.21873/anticanres.12470.
BACKGROUND/AIM: The favorable prognosis of women with non-small-cell lung cancer (NSCLC) compared to men might be explained by sex hormone-related mechanisms. We investigated whether this observation could be explained by the expression of estrogen receptor-alpha (ER-α) in tumor tissue.
MATERIALS AND METHODS
Archived, formalin fixed, paraffin embedded tumor tissue samples were retrospectively analyzed for nuclear expression of ER-α with immunohistochemistry.
RESULTS
Biopsies from 222 patients were analyzed. Twenty-three percent were ER-α positive. Fifty-four percent of the patients were men and 46% of the tumors were adenocarcinomas. One hundred-nine (49%) patients received pemetrexed and carboplatin and 113 (51%) received gemcitabine and carboplatin. Females with ER-α positive tumors who received PC had a substantial survival benefit over all other groups (20 vs. 4.6 months; p=0.003).
CONCLUSION
ER-α is an independent prognostic factor in advanced NSCLC and might also be a predictive factor for response to pemetrexed/carboplatin in women.
背景/目的：与男性相比，非小细胞肺癌（NSCLC）女性患者预后较好，这可能与性激素相关机制有关。我们研究了肿瘤组织中雌激素受体α（ER-α）的表达是否可以解释这一现象。
材料与方法
采用免疫组化方法对存档的、经福尔马林固定、石蜡包埋的肿瘤组织样本进行回顾性分析，检测ER-α的核表达。
结果
分析了222例患者的活检样本。23%为ER-α阳性。54%的患者为男性，46%的肿瘤为腺癌。109例（49%）患者接受培美曲塞联合卡铂治疗，113例（51%）患者接受吉西他滨联合卡铂治疗。接受PC治疗的ER-α阳性肿瘤女性患者的生存期显著优于所有其他组（20个月对4.6个月；p=0.003）。
结论
ER-α是晚期NSCLC的独立预后因素，也可能是女性对培美曲塞/卡铂反应的预测因素。
Zotero 插件